Tinnen Quoted in Reorg About Termination Fees in Alexion Pharmaceuticals Proposed Acquisition of Portola Pharmaceuticals
12 May 2020
Partner Clyde Tinnen was quoted in the Reorg article, “Past Alexion Guidance Bodes Well for Quick Review,” about Alexion’s planned acquisition of Portola in 2020. Although the deal is expected to withstand regulatory scrutiny, Portola would owe Alexion a termination fee in certain circumstances. “All things being equal, break up fees typically do provide a strong protective device for buyers to keep sellers in a deal,” Tinnen said.
(Subscription required)
People
Related News
03 May 2024
In the News
Jeff Symons’ Move to Foley Featured in Press
Foley & Lardner LLP partner Jeff Symons is featured in legal press for his recent arrival to the firm
03 May 2024
In the News
Nathaniel Lacktman on Healthleaders Podcast– ‘We’re seeing maturity in the telemedicine market’
Foley & Lardner LLP partner Nathaniel Lacktman discussed the upcoming American Telemedicine Association’s annual conference, new developments in telemedicine and digital health, the regulatory context, and the prospects for the industry’s future
02 May 2024
In the News
Jennifer Hennessy on American Privacy Rights Act – ‘This law does have teeth’
Foley & Lardner LLP partner Jennifer Hennessy assesses the prospects of what could be the first federal data privacy law passed in the United States